Although more data are needed, our first-in-class report suggests that at this time, there is no contraindication for SRS in patients with NSCLC brain metastasis with an ATM variant seen on a clinical genomic profiling test. The gene discussed is ATM; the disease is non-small cell lung carcinoma.